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Abstract
Introduction: Genome-wide association studies have identified that genetic polymorphisms in the telomerase reverse transcrip-
tase (TERT) and cleft lip and palate transmembrane 1-like (CLPTM1L) genes may play important roles in the development of lung 
cancer in never smokers.
Material and methods: This study was aiming to evaluate the associations between the risk of lung cancer in never smokers 
and single nucleotide polymorphisms in these genes by Real-Time Taqman assay, in forty lung cancer patients and forty appar-
ently healthy age-matched controls selected from the chest department, Kasr Al-Ainy hospital from June 2018 to January 2019. 
Results: Adenocarcinoma was the most common histopathological subtype of lung cancer in the study patients. Also, the 
prevalence of females having adenocarcinoma was more common than males. The heterozygous form of the CLPTM1L occurred 
more frequently in the subjects aged above 46 years (P=0.019). There was a significant association between (rs 2730100) (c. 
1574-3777C>A) TERT and CLPTM1L (rs 451360) (c.1532+ 1051C>A) genotypes and the incidence of lung cancer in never 
smokers, especially adenocarcinoma, a subtype of non-small cell lung carcinoma (NSCLC).
Conclusions: Polymorphism in the telomerase reverse transcriptase (TERT) and cleft lip and palate transmembrane 1 like (CLPT-
M1L) genes may play an important role in the development of NSCLC, especially adenocarcinoma subtype. The two genes are 
located in the chromosome 5p15.33.
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Introduction
From data estimated in 2008, there were 
16,632 newly diagnosed lung cancer cases among 
Arab league countries nationals. The majority of 
cases were reported in Arab countries in North 
Africa such as Egypt (20.6%), followed by Moroc-
co (20.1%), Algeria (15.4%) and Tunisia (10%). 
Furthermore, there were a total of 15,421 deaths 
related to lung cancer in the Arab populations 
[1]. Cancer develops after genetic damage to 
DNA and epigenetic changes. Those changes 
affect the cell’s normal functions, including cell 
proliferation, programmed cell death and DNA 
repair. As more damage accumulates, the risk of 
cancer increases [2]. Studies have demonstrated 
differences in epidemiological characteristics and 
histopathological subtypes between smokers and 
never smokers, which led to the suggestion of 
existence of non-tobacco-related risk factors in 
the pathogenesis of NSCLC. Possible risk factors 
included exposure to cooking fumes, hormones 
and viral infection. Additional evidence that 
suggested differences in tumor biology between 
never smokers and smokers lay in the mutational 
frequencies and spectra observed in the tumor 
tissue itself [3]. 
Genome-wide association studies (GWAS) 
have shown that the polymorphism in the telo-
merase reverse transcriptase (TERT) and cleft 
lip and palate transmembrane 1 like (CLPTM1L) 
genes may play important roles in the develop-
ment of lung cancer. These two genes are located 
in chromosome 5p15.33 [4]. Telomerase expres-
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sion plays a role in cellular senescence as it is 
normally repressed in postnatal somatic cells 
resulting in shortening of telomeres. Deregulation 
of telomerase expression in somatic cells may be 
involved in oncogenesis [5]. CLPTM1L is a com-
monly overexpressed anti-apoptotic factor in lung 
tumors. Knockdown of CLPTM1L transcript in 
NSCLC cells results in the increase in sensitivity 
to genotoxic stress-mediated apoptotic killing 
and diminishes expression of Bcl-xL in a manner 
dependent on a dose of CLPTM1L expression [6]. 
This study investigated the association between 
telomerase reverse transcriptase rs 2736100 (c.1574-
3777C>A) and cleft lip and palate transmembrane 
1 like protein rs 451360 (c.1532+1051C>A) single 
nucleotide polymorphism with lung cancer in 
never smokers. Moreover, it was aiming to figure 
out the relation between the genotypes and tumor 
histopathological subtypes.
Material and methods
This is a prospective study performed in 
the Chest Department in collaboration with the 
Clinical and Chemical Pathology Department, 
Faculty of Medicine, Cairo University during the 
period from June 2018 to January 2019. It was 
performed on 80 subjects divided into two groups; 
Group I included 40 lung cancer never smokers 
recruited from the chest department inpatients 
and diagnosed by bronchoscopic tissue biopsy; 
Group II included 40 age- and sex-matched never 
smokers healthy volunteers as a control group. 
Patients with type II respiratory failure, refractory 
hypoxemia, bleeding disorders, multiple organ 
system failure, recent angina or myocardial in-
farction (< 6 weeks) were excluded. Institutional 
research ethics committee has approved the study 
and written informed consent was obtained from 
all participants. Detection of telomerase reverse 
transcriptase and cleft lip and palate transmem-
brane 1 like protein was done by real-time PCR.
Methodology
Specimen collection: 3 mL of blood were 
withdrawn by aseptic venipuncture to a pre-
chilled violet top EDTA vacutainer tubes for 
genomic DNA study. DNA samples were stored 
at -80˚C to be used for TaqMan real-time PCR.
Genetic analysis of telomerase reverse tran-
scriptase rs 2736100 (c.1574-3777C>A) and cleft 
lip and palate transmembrane 1like protein rs 
451360 (c.1532+1051C>A) by Real-Time PCR: 
Analysis of TERT and CLPTM1L Polymorphisms by 
Real-Time PCR using TaqMan® probes and primers 
on Applied biosystems ®Step One Real-time PCR 
system: The test was done in two main steps:
A. DNA extraction from peripheral blood 
leucocytes of EDTA anti-coagulated blood
Principle: The kit (CinnaPure®DNA) con-
tains all ingredients for quick preparation of pure 
DNA from blood. 
Equipment: Mini spin columns 50×, collec-
tion tubes (1.5 mL) 50×, lysis buffer 20 mL, pre-
cipitation buffer 15 mL, wash buffer I 20 mL, wash 
buffer II 40 mL and elution buffer 2 × 1250 μL.
Protocol: Approximate time for total nucleic 
acid preparation from blood =15 min. Lysis buffer 
(400 μL) was added to 100 μL of the sample in a ster-
ile 1.5 mL polypropylene tube. Precipitation solu-
tion (300 μL) was then added and vortexed at max-
imum speed for 5 seconds. The solution was then 
pipetted to a spin column with a collection tube. 
The tube was centrifuged at 12,100 × g for 1 min., 
after which the collection tube was discarded and 
replaced by a new one. Wash buffer I (400 μL) was 
added to the spin column, centrifuged at 12,100 × 
g for 1 min. and flow-through discarded. The spin 
column was washed with 400 μL wash buffer II, cen-
trifuged for 1 min at 12,100 × g and flow-through 
discarded. This step was repeated twice. The 
column was carefully transferred to a new 1.5 mL 
tube. Preheated elution buffer (30 μL at 65˚C) was 
added to the center of the column which was then 
covered and incubated at 65˚C for 3–5 min. It was 
then centrifuged for 1min. at 12,100 × g to elute the 
DNA. Purified DNA was stored at -80°C. DNA con-
centration was measured spectrophotometrically by 
measuring optical density when ultraviolet light is 
absorbed at 260 nm by Nano drop [7].
B. Amplification and real-time PCR 
allelic discrimination assays
Real-time PCR with sequence-specific primers 
was used to assess the telomerase reverse tran-
scriptase and cleft lip and palate transmembrane 
1like protein. Real-time PCR allelic discrimination 
assay were designed using TaqMan SNP Genotyp-
ing Assays (Applied Bio systems) (Figure 1).
Principle. TaqMan SNP Genotyping Assay
1. Each TaqMan Minor groove binder (MGB) 
probe anneals specifically to its complementa-
ry sequence between the forward and reverse 
primer sites.
2. When the oligonucleotide probe is intact, the 
proximity of the reporter dye to quencher dye 
results in quenching of reporter fluorescence. 
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Figure 1 A. Allelic discrimination plot of TERT (rs 2736100). B. Allelic discrimination plot of CLPT1L (rs 451360). C. Multicomponent plot of TERT 
(rs 2736100). D. Multicomponent plot of CLPT1L (rs 451360). After PCR amplification, real-time PCR allelic discrimination assays were designed 
using TaqMan SNP genotyping assay (Applied Bio systems). The Sequence Detection System (SDS) Software used the fluorescence measurements 
made during the plate read to plot fluorescence values based on the signals from each well. Plotted fluorescence signals indicated which alleles 
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3. AmpliTaq Gold DNA polymerase extends prim-
ers bound to template DNA.
4. AmpliTaq Gold DNA polymerase cleaves only 
probes that are hybridized to target.
5. Cleavage separates reporter dye from quencher 
dye, which results in increased fluorescence 
by reporter.
6. Increase in fluorescence signal occurs when 
probes that have hybridized to complementary 
sequence are cleaved. Thus, fluorescence sig-
nal generated by PCR amplification indicates 
which alleles are present in the sample [8].
Reagents
Each of the 40× TaqMan SNP Genotyping Assay 
consists of a single tube containing:
1. Sequence-specific forward and reverse primers 
to amplify promoter region of CLPTM1L and 
TERT genes.
2. Two TaqMan MGB probes for distinguishing 
between the two alleles:
 — One probe labeled with VIC dye detects 
Allele 1 sequence.
 — One probe labeled with FAM dye detects 
Allele 2 sequence:
• The context sequence for TERT was 
Polymorphism: C > A, transition sub-
stitution.
• The context sequence for CLPTM1L was 
Polymorphism: C > A, transversion 
substitution.
Each TaqMan MGB probe contains:
1. Reporter dye at the 5’ end of each probe.
 — FAM dye (6-carboxyfluorescein) is linked 
to the 5’ end of the Allele 1 (C) probe.
 — VIC dye is linked to the 5’ end of the Allele 
2 (A) probe.
2. Minor groove binder (MGB) at the 3’ end of 
each probe. This modification increases melt-
ing temperature (Tm) for a given probe length 
[9], which allows the design of shorter probes.
3. Non-fluorescent quencher (NFQ) at the 3’ end 
of each probe.
Technique
All reactions were performed in total volume 
of 20 μL containing 10 μL of master mix, 0.5 μL 
of SNP-ready-made assay, (1–5 μL) purified DNA 
solution according to DNA concentration which 
was measured to be completed to 20 μL of nucle-
ase-free water. Reaction mixture was prepared 
for each assay before transferring it to the optical 
reaction plate for thermal cycling. After adding 
reagents to DNA samples, they were mixed thor-
oughly to avoid air bubbles in the well.
Allelic discrimination plate read 
and analysis
After PCR amplification, an endpoint plate 
read was performed using an Applied Bio systems 
Real-Time PCR System, The Sequence Detection 
System (SDS) Software used the fluorescence 
measurements made during the plate read to plot 
fluorescence values based on the signals from 
each well. Plotted fluorescence signals indicated 
which alleles were in each sample. Plate read 
document was analyzed. Automatic allele calls 
were made. Allele calls were converted to geno-
types (Figure 1).
Statistical methods
Data were coded and entered using the sta-
tistical package SPSS version 23. Data were 
summarized using mean, standard deviation, 
median, minimum and maximum for quantitative 
variables and frequencies (number of cases) and 
relative frequencies (percentages) for categori-
cal variables. Comparisons between the groups 
were done using unpaired t test when comparing 
2 groups and analysis of variance (ANOVA) with 
multiple comparisons post hoc test when com-
paring more than 2 groups. For comparing cate-
gorical data, Chi-square (c2) test was performed. 
Exact test was used instead when the expected 
frequency was less than 5.  Genotype and allele 
frequencies were compared between the disease 
and the control groups using logistic regression. 
Odds ratio (OR) with 95% confidence intervals 
was calculated.  P-values less than 0.05 were 
considered  statistically significant [10].
Results
Group (I) included 40 lung cancer non-smok-
ers, their mean age was 44.13 + 16.18. There 
were 20 females (50%) and 20 males (50%) in 
the group. Group (II) included forty healthy vol-
unteers serving as a control group. Their mean 
age was 34.45 + 9.98 years, and there were 
31 females (77.5%) and 9 males (22.5%). Never 
smoker lung cancer patients were classified into 
small-cell lung carcinoma (SCLC) constituting 
5% (2 patients), undifferentiated lung carcino-
ma constituting 5% (2 patients) and 36 (90%) 
non-smallcell lung carcinoma (NSCLC) cases, 
who were divided into 26 (65%) adenocarcinoma 
cases, 6 (15%) large-cell carcinoma and 4 (10%) 
squamous-cell carcinoma (Figure 2).
TERT genotype distribution showed that 
homozygous form of the wild genotype “CC” 
was found in 22 (55%) patients and 18 (45%) 
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individuals of the control group with no clinical 
significance (P=0.2). The heterozygous form of 
genotype “CA” was found in 12 (30%) patients 
and 19 (47.5%) control individuals (P=0.175) 
and the homozygous form of the mutant geno-
type “AA” was found in 6 (16%) patients and in 
3 (7.5%)  controls (P=0.525). The allelic distribu-
tion of TERT showed that “A” allele was present 
in 24 (30%) patients and 25 (31.3%) controls (P 
= 0.864), and allele “C” was found in 56 (70%) 
patients and 55 (68.8%)  controls (P = 0.932) 
(Figure 3A). The genotype distribution of the 
CLPTM1L showed that the homozygous form of 
the mutant genotype “AA” was found in 9 (22%) 
patients in the never smoker lung cancer group, 
while it was found in 6 (12%) individuals in 
the control group with no clinical significance 
(P = 0.393). The heterozygous form “CA” was 
discovered in 31 (77.5%) patients, while it was 
found in 34 (85%) individuals of the control 
group (p = 0.53), and the homozygous form of 
the wild genotype “CC” was not detected in the 
two studied groups. The allelic distribution of 
the CLPTM1L revealed that allele “A” was found 
in 49 (61.3%) patients and 46 (57.5%)  controls 
(P = 0.629), and the “C” allele was discovered in 
31 (38.8%) patients and 34 (42.5%)  controls (p 
= 0.512) (Figure 3B).
On combining genotypes of TERT and CLPT-
M1L, the homozygous form of the wild genotype 
“CC” of the TERT and the homozygous form of the 
mutant genotype “AA” of CLPTM1L was found in 
1 patient and in 1 control individual constituting 
2.5% of each group (P = 0.884). On joining the 
homozygous form of the mutant genotypes “AA” of 
both SNPs (single nucleotide polymorphisms), it 
was found in 3 patients (7.5%) and in 2 controls 
(5%) (P = 0.841). On combining the homozygous 
form of the mutant genotype “AA” of TERT with 
the heterozygous form “CA” of the CLPTM1L, it 
was found in 3 patients (7.5%) and in 1 (2.5%) 
of the controls (P = 0.460). On combining the 
heterozygous form “CA” of TERT with the ho-
mozygous form “AA” of the mutant genotype of 
CLPTM1L, it was found in 5 (12.5%) lung cancer 
patients and in 3 (7.5%) controls (P = 0.708). On 
combining the heterozygous form ”CA” of the two 
SNPs, it was found in 7 (17.5%) patients and in 
16 (40%) controls (P = 0.06), and on joining the 
homozygous form of the wild genotype “CC” of 
TERT with the heterozygous form “CA” of CLPT-
M1L, it was found in 21 (52.5%) patients and in 
17 (42.5%)  controls (P = 0.978).
The relations between TERT and CLPTM1L 
genotypes and the histopathological subtypes of 
lung cancer were shown in Table 1 and 2. Also, 
relations between the combination of genotypes 
of two SNPs and lung cancer histopathology were 
shown in Table 3. The connection between the 
genotypes or the combination of genotypes of two 
SNPs and sex showed no statistical significance. 
The relation of the CLPTM1L genotypes and age 
uncovered that mean age of patients with het-
erozygous form of CLPTM1L “CA” was 46.42 ± 
17.28 years, while mean age of patients who had 
homozygous form of the mutant genotype was 
36.22 ± 8.09 (P = 0.019). The relation between 
genotypes of TERT and age showed that mean 
age of patients with heterozygous form “CA” was 
44.17 + 15.58 years, and mean age of homozygous 
form of wild genotype “CC” was 46.68 + 17.51, 
and these are older ages than the ages (34.67 + 
9.18) of the patients showing homozygous form 
of mutant genotype “AA” (P = 0.27).
Discussion
Lung cancer is one of the commonest cancer 
types worldwide in respect of incidence and 
mortality. Global statistical data showed that 
lung cancer alone accounts for 13% of all newly 
diagnosed cancers and is responsible for 18% 
of all cancer deaths [11]. Lung cancer in never 
smokers is distinct from those in smokers in view 
of pathogenesis, molecular alterations, drug re-
sponsiveness and prognosis. Significant portion 
Figure 2. Classification of never smoker lung cancer patients accord-
ing to the histopathological type of the tumor
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Figure 3 A. Genotype and allelic distribution of TERT (rs 2736100) (c. 1574-3777A>C). B. Genotype and allelic distribution of CLPT1L (rs 451360) 
(c. 1532 + 1051A>C)
A
B
of lung cancer in never smokers harbor genetic 
variant in driving oncogene, to which molec-
ular targeted drugs are dramatically sensitive. 
Therefore, genetic testing before the treatment 
is essential for lung cancer in never smokers to 
select the appropriate treatment option according 
to patient’s molecular characteristics [12].
Non-smoking-associated lung cancer  not 
only occurs in never smokers, but also in cur-
rent and former smokers. Recent genome-wide 
association studies (GWAS) have shown that the 
polymorphisms in the TERT and CLPTM1L genes 
may play important roles in the development of 
lung cancer. The two genes are both located in 
chromosome 5p15.33 [13]. Three GWAS in Euro-
pean populations showed consistent associations 
of polymorphisms in these two genes with lung 
cancer in non-smokers [14].
This study analyzed the distribution of TERT 
and CLPTM1L single nucleotide polymorphism 
in patients with lung cancer in never smokers 
and in healthy controls in attempt to find the 
association between these two polymorphisms 
and the development of lung cancer in never 
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NSCLC (n = 36) Yes [no, %] 5 (83.33%) 11(91.67%) 20 (90.91%) 36 (90%) 0.837
No [no, %] 1 (16.67%) 1 (8.33%) 2 (9.09%) 4 (10%)
SCLC (n = 2) Yes [no, %] 0 0 2 (9.09%) 2 (5%)
0.422No [no, %] 6 (100%) 12 (100%) 20 (90.91%) 38 (95%)
Undifferentiated 
carcinoma (n = 2)
Yes [no, %] 1 (16.67%) 1 (8.33%) 0 2 (5%) 0.206
No [no, %] 5 (83.33%) 11 (91.67%) 22 (100%) 38 (95%)
P-value 0.005* 0.0001* 0.0001* 0.0001*
Histopathological subtype










NSCLC (n = 36) Yes [no, %] 8 (88.89%) 28 (90.32%) 0 36 (90%) 0.899
No [no, %] 1 (11.11%) 3 (9.68%) 0 4 (10%)
SCLC (n = 2) Yes [no, %] 0 (0.0%) 2 (6.45%) 0 2 (5%) 0.434
No [no, %] 9 (100%) 29 (93.55%) 0 38 (95%)
Undifferentiated 
carcinoma (n = 2)
Yes [no, %] 1 (11.11%) 1 (3.23%) 0 2 (5%) 0.339
No [no, %] 8 (88.89%) 30 (96.77%) 0 38 (95%)
P-value 0.0007* 0.0001* — 0.0001*
*P value < 0.05 is considered significant.
NSCLC — non-small cell lung carcinoma; TERT — telomerase reverse transcriptase; SCLC —small cell lung carcinoma
smokers. Never smokers lung cancer patients 
were classified according to histopathological 
subtype of lung cancer into small-cell lung car-
cinoma (5%), undifferentiated lung carcinoma 
(5%) and non-small-cell lung carcinoma (90%). 
Then NSCLC patients were further divided into 
adenocarcinoma (65%), large-cell carcinoma 
(15%), squamous-cell carcinoma (10%) (Figure 
2). Adenocarcinoma was most prevalent subtype. 
This agreed with Sun et al. [15] who stated that 
smoking-related carcinogens act on both proxi-
mal and distal airways of the lung inducing all 
major types of lung cancer. Also, they stated 
that cancers arising in never smokers target 
distal airways and favor the adenocarcinoma 
type. Subramanian and Govindan [16] mentioned 
that adenocarcinoma is the most common type 
occurring in never smokers. Again, Landi et al. 
[17] have established that locus on chromosome 
5p15.33 is distinctly associated with a risk of 
lung adenocarcinoma and not with other major 
histological types. Also, Henschke et al. [18] 
found that women are commonly diagnosed when 
screened, and Patel et al. [19] showed that wom-
en outnumber men among lung cancer patients 
who never smoked regularly. The study done by 
Samet et al. [20] showed that adenocarcinoma 
is more prevalent in females. This is explained 
by the hypothesis that females are more prone 
to exposure to second-hand smoke, household 
exposure of coal used for cooking, hormone re-
placement therapy, use of antiaging drugs which 
elongate telomeres thus escaping apoptosis and 
lead to cancers [21].
In the present study, there was a statistically 
significant difference in mean age between the 
patients demonstrating heterozygous form of 
CLPTM1L “CA” and those showing homozygous 
form of mutant genotype AA” (P = 0.019). Al-
though age difference between different genotype 
of TERT was statistically insignificant (P = 0.27), 
the patients with heterozygous form CA and 
homozygous form of wild genotype “CC” were 
older  than patients showing homozygous form of 
mutant genotype “AA”. This agreed with Wakelee 
et al. [22] who mentioned that lung cancer in 
never smokers occurs more commonly after the 
age of forty.
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Table 2. The relation between histopathological subtypes of non-small cell lung cancer and TERT and CLPT1L genotypes 













(n = 26) 
Yes (no, %) 2 (40%) 8 (72.73%) 16 (80%) 26 (72.22%) 0.202
No (no, %) 3 (60%) 3 (27.27%) 4 (20%) 10 (27.78%)
Squamous cell car-
cinoma (n = 4)
Yes (no, %) 2(40%) 0 2 (10%) 4 (11.11%) 0.004*
No (no, %) 3 (60%) 11 (100%) 18 (90%) 32 (88.89%)
Large cell carcinoma 
(n = 6)
Yes (no, %) 1 (20%) 3 (27.27%) 2 (10%) 6 (16.67%) 0.455
No (no, %) 4 (80%) 8 (72.73%) 18 (90%) 30 (83.33%)
P-value 0.740 0.001 0.0001 0.001
NSCLC histopathological subtypes












Yes (no, %) 6 (75%) 20 (71.43%) 0 26 (72.22%) 0.841
No (no, %) 2 (25%) 8 (28.57%) 0 10 (27.78%)
Squamous cell 
carcinoma (n = 4)
Yes (no, %) 0 4 (14.29%) 0 4 (11.11%) 0.256
No (no, %) 8 (100%) 24 (85.71%) 0 32 (88.89%)
Large cell carcinoma 
(n = 6)
Yes (no, %) 2 (25%)  4 (14.29%) 0 6 (16.67%) 0.473
No (no, %) 6 (75%) 24 (85.71%) 0 30 (16.67%)
P-value 0.005* 0.0001* — 0.001*
*P value <0.05 is considered significant.
NSCLC — non-small cell lung carcinoma; TERT — telomerase reverse transcriptase; SCLC — small cell lung carcinoma














Adenocarcinoma 1 (100%) 2 (66.7%) 0 3 (60%) 5 (71.4%) 15 (71.4%) < 0.001*
Squamous cell carcinoma 0 0 2 (66.7%) 0 0 2 (9.5%) 0.15
Large cell carcinoma 0 1 (33.3%) 0 1 (20%) 2 (28.6%) 2 (9.5%) 0.54
SCLC 0 0 0 0 0 2 (9.5%) 0.07
Undifferentiated carcinoma 0 0 1 (33.3%) 1 (20%) 0 0 0.54
P 0.4 0.25 0.25 0.19 0.008* < 0.001*
*P value <0.05 is considered significant.
SCLC —small cell lung carcinoma
There was no statistically significant differ-
ence between never smoker lung cancer patients 
and the controls in TERT genotype distribution re-
garding homozygous form of wild genotype “CC”, 
heterozygous form of genotype “CA” and homozy-
gous form of mutant genotype “AA”. Also, allelic 
distribution of TERT showed that the “A” allele and 
allele “C” didn’t differ in distribution between the 
cases and controls. Wang et al. [23] showed that 
TERT SNPs is a risk factor for developing lung can-
cer in never smokers. Again, case–control study by 
Liao et al. [24] revealed the statistical significance 
between AC and CC genotypes, as well as C allele 
of rs2736100 in TERT gene and increased risks of 
lung cancer in never smokers. This is explained by 
various ethnic populations, besides, a difference 
in defining investigating groups and small sample 
size,  a dissimilarity in their genetic backgrounds, 
geographical differences in allelic frequencies and 
complexity of the disease.
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The distribution of CLPT1L genotypes and 
allelic distribution showed non-significant differ-
ence between never smoker lung cancer patients 
and healthy controls. Also, Sun et al. [25] found 
no association of XRCC1 and CLPTM1L polymor-
phisms with NSCLC in non-smoking Han Chinese 
population. However, Pande et al. [26] revealed 
additional SNPs that may be susceptibility mark-
ers for lung cancer risk in smokers (rs4975615) 
and never smokers (rs451360) of clinical signifi-
cance. Also, the case-control study by Liang et al. 
[27] found that rs451360, an intronic SNP within 
CLPTM1L gene, was significantly associated 
with lung cancer risk in never smokers. Possible 
explanations for the same polymorphism to have 
different roles in cancer susceptibility can occur 
because that allele under investigation can be 
masked by the presence of other genes involved 
in disease development. Thus, results available 
regarding effect of polymorphisms on cancer 
risk and development should be interpreted with 
caution. 
TERT genotypes including homozygous form 
of mutant genotype “AA”, heterozygous form “CA” 
and homozygous form of wild genotype “CC” were 
significantly found in NSCLC patients constitut-
ing 83.33%, 91.67% and 90.91%, respectively, 
of lung cancer non-smoker patients. CLPTM1L 
genotypes including homozygous form of mutant 
allele “AA” and heterozygous genotype “CA” were 
detected significantly in NSCLC patients consti-
tuting 88.89% and 90.32%, respectively (Table 2). 
TERT and CLPTM1L genotypes were significantly 
presented in adenocarcinoma compared to squa-
mous-cell carcinoma and large-cell carcinoma 
(Table 3). On combining homozygous form of 
wild genotypes “CC” of TERT and homozygous 
form of mutant genotype “AA”, was found in ad-
enocarcinoma (100%). On joining homozygous 
form of mutant genotype “AA” in both SNPs, was 
found in adenocarcinoma (66.7%) and large-cell 
carcinoma (33.3%). On combining homozygous 
form of mutant genotype of TERT “AA” with het-
erozygous form of CLPTM1L “CA”, was found in 
squamous-cell carcinoma (66.7%) and undifferen-
tiated carcinoma (33.3%). On combining hetero-
zygous form of TERT “CA” with homozygous form 
of mutant genotype of CLPTM1L “AA”, was found 
in adenocarcinoma (60%), large-cell carcinoma 
(20%) and undifferentiated carcinoma (20%). 
On combining heterozygous form “CA” of both 
SNPs, was found in adenocarcinoma 5 (71.5%) 
and large-cell carcinoma (28.6%) with statistical 
significance (P=0.008). On combining homozy-
gous form of wild genotype of TERT “CC” with 
heterozygous form of CLPT1L (CA), was found in 
adenocarcinoma (71.4%), squamous-cell carcino-
ma (9.5%), large-cell carcinoma (9.5%), small-cell 
carcinoma (9.5%) with statistical significance (P 
< 0.001). Also, there was statistical significance 
regarding the association of adenocarcinoma 
and some combined genotypes, mainly “CC/AA, 
CA/CA and CC/CA” (P ≤ 0.001). This agreed with 
Yuan et al. [28] who demonstrated that TERT rs 
2736100 polymorphism is a risk factor associ-
ated with increased lung cancer susceptibility, 
particularly for lung adenocarcinoma. Also, Hsi-
ung et al. [29] reported conclusive evidence that 
common genetic variants in TERT-CLPTM1L lo-
cus on chromosome 5p15.33 are associated with 
a risk for lung adenocarcinoma in non-smoking 
Asian women. Again, Zhao et al. [30] showed 
a significant association of 5p15.33 (TERT–CLPT-
M1L genes) with lung cancer in the Chinese Han 
population.
Again, Bhat et al. [31] suggested that 
rs2853677 of TERT was significantly  associated 
with multiple cancers, and it could be a potential 
marker for diagnosis of non-small-cell lung cancer 
and leukemia. Our study together with Bhat et al 
study highlighted the role of telomere-associat-
ed pathways in non-small-cell lung cancer. On 
the other hand, Hung et al. [32] suggested that 
SNPs/regions connected with lung cancer risk in 
never smokers are not specific for this type of can-
cer but rather have pleiotropic effects. Also, they 
found that genetic susceptibility to lung cancer in 
never smokers is associated with genetic variants 
with pan-cancer risk effects, and they mentioned 
that the comparison with smokers discovered that 
top variants previously shown to be associated 
with lung cancer risk only confer risk in the 
presence of tobacco exposure, underscoring the 
importance of gene-environment interactions in 
the etiology of this disease. Similarly, Wang et al. 
[33] performed a pleiotropic analysis to explore 
the shared susceptibility mechanisms between 
non-lung cancers and lung cancer and found 
that genetic variants identified from other cancer 
types were also significantly associated with the 
risk of lung cancer.
In conclusion, polymorphism in TERT and 
CLPTM1L genes may play an important role in the 
development of NSCLC, especially the adenocar-
cinoma subtype. The two genes are located in the 
chromosome 5p15.33. It is necessary to conduct 
large-scale population study on Egyptian patients 
to elucidate our results. It is recommended to do 
further studies using more advanced molecular 
techniques as complete sequence analysis for 
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proper evaluation and assessment of the TERT 
and CLPT1L single nucleotide polymorphism as 
a predictive marker of lung cancer in Egyptian 
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